Back to News
Market Impact: 0.25
Insilico Medicine Doses First Patient in GENESIS-IPF-3, the World's First Phase III Trial of a Generative AI-Driven Innovative Drug
Source: PR Newswire
Healthcare & BiotechArtificial IntelligenceTechnology & Innovation
Insilico Medicine announced that the first patient has been dosed with Rentosertib (ISM001-055/INS018_055) in the GENESIS-IPF-3 clinical trial. The milestone advances the company’s generative-AI-enabled drug-development pipeline, though the article excerpt provides no efficacy, safety, enrollment, or financial data.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
More News
- Here’s the ‘core economic flaw’ in the AI bull case as stock and bond trades unravel, according to a top economist
- Biotech stocks are surging. How investors can play the new drug innovation boom
- AI funding fears rattle Wall Street. Here's how we're adjusting our portfolio
- Nvidia's role as AI financier faces first big test as neoclouds take market hit
- Ukraine says Starlink and Starshield high speed restrictions have been lifted
- Goldman says these top tech stocks have plenty of upside ahead of earnings